Full Text View
Tabular View
No Study Results Posted
Related Studies
Effect of Intravenous Ceftriaxone and Oral Doxycycline for Lyme Neuroborreliosis
This study is currently recruiting participants.
Verified by Sorlandet Hospital HF, March 2005
First Received: August 29, 2005   Last Updated: December 14, 2005   History of Changes
Sponsor: Sorlandet Hospital HF
Information provided by: Sorlandet Hospital HF
ClinicalTrials.gov Identifier: NCT00138801
  Purpose

The aim of this study is to compare parenteral ceftriaxone and oral doxycycline in the treatment of neuroborreliosis in a randomized controlled trial.


Condition Intervention Phase
Lyme Neuroborreliosis
Drug: Ceftriaxone
Drug: Doxycycline
Phase III

Study Type: Interventional
Study Design: Diagnostic, Randomized, Double-Blind, Active Control, Parallel Assignment, Efficacy Study
Official Title: Effect of Intravenous Ceftriaxone and Oral Doxycycline for Lyme Neuroborreliosis. A Randomized Double-Blind Comparison

Resource links provided by NLM:


Further study details as provided by Sorlandet Hospital HF:

Study Start Date: March 2004
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Neurological symptoms and/or findings consistent with neuroborreliosis and at least one of the following fulfilled:

    • Intrathecal production of borrelia antibodies;
    • White cell count in cerebrospinal fluid (CSF) > 5/mm3;
    • Significant rise in borrelia antibodies in two serum samples collected from a patient with at least 3 weeks interval;
    • Verified acrodermatitis chronica atrophicans.

Exclusion Criteria:

  • Allergy to the contents in the medication, or earlier type I reaction to penicillin.
  • Treatment with cephalosporins, penicillin or tetracyclins during the last 14 days
  • Pregnancy or breastfeeding
  • Age < 18 years
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00138801

Contacts
Contact: Unn Ljøstad, MD ++4738073910 unn.ljostad@sshf.no

Locations
Norway, Vest-Agder
Sørlandet Sykehus HF Recruiting
Kristiansand, Vest-Agder, Norway, 4633
Contact: Svein Gunnar Gundersen, MD, PhD     ++4738073000     s.g.gundersen@sshf.no    
Principal Investigator: Unn Ljøstad, MD            
Sponsors and Collaborators
Sorlandet Hospital HF
Investigators
Study Chair: Åse Mygland, MD, PhD Sorlandet Sykehus HF
  More Information

No publications provided by Sorlandet Hospital HF

Additional publications automatically indexed to this study by National Clinical Trials Identifier (NCT ID):
Study ID Numbers: SSHF70204
Study First Received: August 29, 2005
Last Updated: December 14, 2005
ClinicalTrials.gov Identifier: NCT00138801     History of Changes
Health Authority: Norway: Directorate for Health and Social Affairs

Keywords provided by Sorlandet Hospital HF:
Neuroborreliosis

Additional relevant MeSH terms:
Bacterial Infections
Anti-Infective Agents
Antiprotozoal Agents
Borrelia Infections
Lyme Disease
Nervous System Diseases
Central Nervous System Diseases
Ceftriaxone
Pharmacologic Actions
Tick-Borne Diseases
Gram-Negative Bacterial Infections
Antimalarials
Anti-Bacterial Agents
Antiparasitic Agents
Central Nervous System Infections
Spirochaetales Infections
Therapeutic Uses
Central Nervous System Bacterial Infections
Lyme Neuroborreliosis
Doxycycline

ClinicalTrials.gov processed this record on November 27, 2009